Balboa Wealth Partners Purchases 8,764 Shares of Novo Nordisk A/S (NYSE:NVO)

Balboa Wealth Partners grew its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 442.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 10,745 shares of the company's stock after acquiring an additional 8,764 shares during the quarter. Balboa Wealth Partners' holdings in Novo Nordisk A/S were worth $924,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Center for Financial Planning Inc. increased its holdings in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after buying an additional 123 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S in the third quarter worth about $28,000. Albion Financial Group UT grew its position in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC increased its stake in Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after acquiring an additional 243 shares during the last quarter. Finally, Hager Investment Management Services LLC purchased a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $46,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 4.3 %

Shares of NYSE:NVO opened at $74.75 on Thursday. The business's 50 day moving average is $84.39 and its 200 day moving average is $103.83. The stock has a market cap of $335.42 billion, a P/E ratio of 22.72, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $73.80 and a 52-week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio (DPR) is 47.72%.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent research reports. BMO Capital Markets decreased their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.